---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Mechanism of action"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Mechanism of action. Topics: Humanized monoclonal antibody that binds KIT and blocks SCF binding and KIT dimerization, Allosteric inhibition through the membrane-proximal dimerization domains of KIT, Selectivity and inhibition of SCF-dependent KIT phosphorylation and mast cell degranulation, Fc substitutions that abolish effector function and reduce clearance, and 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Humanized monoclonal antibody that binds KIT and blocks SCF binding and KIT dimerization

> “Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT and potently inhibits its activity.”
> “KIT is expressed in a variety of cells, including mast cells, and its activation by its ligand SCF regulates mast cell growth, differentiation, survival, chemotaxis and degranulation.”
> “Barzolvolimab is designed to block KIT activation by disrupting both SCF binding and KIT dimerization.”
> “By targeting KIT, barzolvolimab has been shown to inhibit mast cell activity and decrease mast cell numbers, which we believe could provide potential clinical benefit in mast cell related diseases.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity.”
> “The KIT receptor is abundantly expressed by mast cells and critical for their function and survival.”
> “Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.6.1-2"></a>

### Allosteric inhibition through the membrane-proximal dimerization domains of KIT

> “CDX‐0159 is a humanized IgG1/κ monoclonal antibody with a modified Fc domain that was derived from CDX‐0158, a predecessor anti‐KIT antibody with an unmodified IgG1/κ backbone.”
> “The antibody was developed from mice immunized with the membrane proximal dimerization domains (Ig 4 and 5) of human KIT (huKIT‐D4D5), which are required for KIT activation by SCF but are not directly involved in ligand binding.”
> “CDX‐0159 bound to KIT naturally expressed in the surface of megakaryoblastic leukemia M‐07e cells with an EC50 of 153 ± 22 pM (Figure 1B), and completely blocked binding of fluorescently labeled SCF to M‐07e cells with an IC50 value of 118 ± 6 pM (Figure 1C).”
> “CDX‐0159 allosterically blocks binding of SCF to KIT, which may result in an elevation of SCF plasma levels from accumulating unbound SCF.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “Barzolvolimab (CDX-0159) is a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody (mAb) that binds the extracellular domain of KIT with high specificity and sub-nanomolar affinity, and allosterically inhibits activation by SCF.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-3"></a>

### Selectivity and inhibition of SCF-dependent KIT phosphorylation and mast cell degranulation

> “Furthermore, CDX‐0159 bound specifically to KIT but not to other related type‐III receptor tyrosine kinases (Figure S2).”
> “Similarly, titration of CDX‐0159 on CHO cells stably transfected to express human KIT (CHO‐KIT) inhibited SCF‐dependent KIT phosphorylation (Figure 1D) with an IC50 of 232 ± 4 pM, or 2–3 orders of magnitude more potently than FDA‐approved KIT‐targeting TKIs imatinib, pexidartinib, and avapritinib (IC50 = 931 ± 78 nM, 87 ± 7 nM, and 175 ± 59 nM, respectively).”
> “In this assay, CDX‐0159 titration fully inhibited SCF‐dependent MC degranulation (IC50 = 650 ± 88 pM) (Figure 1F).”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.6.1-4"></a>

### Fc substitutions that abolish effector function and reduce clearance

> “To eliminate the potential for FcγR crosslinking and effector functions, we engineered 3 amino acid substitutions (L234A/L235Q/K322Q) in the Fc region of CDX‐0158 predicted to abolish FcγR binding and expected to similarly impact C1q receptor binding.”
> “In addition, we also incorporated a set of modifications (M252Y/S254T/T256E)—herein named YTE—that increase the binding affinity for the neonatal Fc receptor (FcRn) which enhances the pharmacokinetic (PK) properties of the mAb by reducing the rate of in vivo clearance.”
> “Taken together, these data demonstrate that the Fc modifications in CDX‐0159 effectively abolish Fc‐dependent effector function and agonist activity leading to MC degranulation.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “Modifications to the Fc fragment of barzolvolimab eliminated FcγR binding and the potential for significant infusion-related reactions through Fc-mediated MC activation, and enhanced antibody serum exposure in non-human primates.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-5"></a>

### KIT expression on mast cells and on other cell types

> “The KIT (c‐KIT/CD117) receptor tyrosine kinase and its only ligand stem cell factor (SCF) are master regulators of MC biology.”
> “KIT is highly expressed throughout the life of a MC and is also expressed in hematopoietic stem cells, melanocytes, interstitial cells of Cajal, germ cells, and a subset of taste receptor cells.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “KIT activation by SCF in follicular melanocytes participates in their terminal differentiation and maturation but is not expressed in melanocyte stem cells.”
> “Similarly, KIT expression has been reported in mature T1R3-positive type II taste cells”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-6"></a>

### Mast cell depletion as the hypothesized basis of benefit in CSU

> “Barzolvolimab—a monoclonal anti‐KIT antibody—depletes MCs by inhibiting activation of KIT by stem cell factor.”
> “Barzolvolimab, as a potent inhibitor of SCF‐dependent KIT activation in cells, is hypothesized to provide therapeutic benefit in patients with CSU by decreasing the number of MCs and their activity.”
> “These results support the anti‐KIT mechanism of action for treating CSU.”
> “Patients had similar symptom improvement irrespective of prior omalizumab use, suggesting that barzolvolimab can help improve urticaria symptoms regardless of whether IgE is the underlying trigger.”
> “The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.1-7"></a>

### Wild-type and KITD816V mast cell models: apoptosis and SCF-enhanced IgE-mediated activation

> “We established and characterized primary-like human MC models, including isogenic human induced pluripotent stem cell-derived WT and heterozygous KITD816V MCs, peripheral CD34+ stem cell-derived MCs, and HMC-1.2 cell line.”
> “Barzolvolimab induced dose-dependent apoptosis and inhibited stem cell factor-induced KIT signaling in WT MCs, but it had no effect on mutant MC viability or signaling.”
> “Notably, barzolvolimab effectively suppressed stem cell factor-enhanced IgE-mediated MC activation across all primary-like models, including KITD816V MCs, as evidenced by reduced β-hexosaminidase release and CD63 expression.”
> “This inhibitory effect occurred at low nanomolar concentrations and was independent of cytotoxicity.”

Source: [Hu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42697278/)

<a id="topic-2.1.2.6.1-8"></a>

### Cold urticaria and symptomatic dermographism: skin mast cells as the effector cells

> “This study also highlights the striking reliance of skin mast cells on KIT/SCF signaling and provides the first direct demonstration that skin MCs are the key effector cells in ColdU and SD.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-9"></a>

### Eosinophilic esophagitis: mast cell depletion without improved clinical outcomes

> “Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract”
> “Profound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.2.6.1-10"></a>

### Prurigo nodularis: mast cell depletion without improvement in itch or skin lesions

> “Profound mast cell depletion as evidenced by significant reduction in serum tryptase was observed and did not result in improvement in itch or skin lesions in patients with PN compared to placebo, indicating mast cells may not be a key pathogenic driver of symptoms in PN.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
